Postmarketing reporting profile of mirikizumab in ulcerative colitis: a disproportionality analysis of FAERS reports. // Clinical Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0149291826003449?dgcid=rss_sd_all
Postmarketing reporting profile of mirikizumab in ulcerative colitis: a disproportionality analysis of FAERS reports. Clinical Therapeutics. https://www.sciencedirect.com/science/article/pii/S0149291826003449?dgcid=rss_sd_all
“Postmarketing reporting profile of mirikizumab in ulcerative colitis: a disproportionality analysis of FAERS reports.” Clinical Therapeutics.
@article{article41730,
title = {Postmarketing reporting profile of mirikizumab in ulcerative colitis: a disproportionality analysis of FAERS reports},
journal = {Clinical Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0149291826003449?dgcid=rss_sd_all}
}